Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Onychomycosis Market from 2024 to 2025?

The size of the onychomycosis market has seen robust growth in the past few years. It is expected to escalate from $3.63 billion in 2024 to $3.83 billion in 2025, marking a compound annual growth rate (CAGR) of 5.4%. The historical expansion can be linked to several factors including constrained therapy choices, growing elder population, a heightened prevalence of diabetes, the broadening of the pharmaceutical industry, and an increased alertness about fungal infections.

What Is the Projected Market Size of the Onychomycosis Market?

In the coming years, the onychomycosis market is predicted to witness significant growth, with its value expected to reach $4.81 billion in 2029, reflecting a compound annual growth rate (CAGR) of 5.9%. The predicted growth for the forecast period can be attributed to factors like the use of combination drug therapies, enhanced healthcare spending, ongoing awareness campaigns about onychomycosis, the growth of telemedicine services, and the advancement in topical drug therapies. The market trends to watch out for in the forecast period include the adoption of digital technologies in diagnosing and managing onychomycosis, increased availability of over-the-counter (OTC) antifungal products, the creation of more patient-friendly treatment plans, the focus on personalized medicine for onychomycosis treatment, and collaborations between pharmaceutical firms for research and development.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12197&type=smp

Who are the Major Competitors in the Onychomycosis Market Outlook?

Major companies operating in the onychomycosis market include Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Sandoz International GmbH, Bausch Health Companies Inc., Perrigo Company plc, Galderma Laboratories LP, Aurobindo Pharma Limited, Cipla Inc., Dr.Reddy’s Laboratories Ltd., Apotex Inc, Lupin Limited, Amneal Pharmaceuticals Inc., Alembic Pharmaceuticals Inc., Kaken Pharmaceutical Co. Ltd., Mayne Pharma Group Limited, Wockhardt Ltd., Jubilant Cadista Pharmaceuticals Inc., Moberg Pharma AB, Medimetriks Pharmaceuticals Inc., Blueberry Therapeutics Ltd., Hallux Inc., NovaBiotics Ltd., Zydus Cadila Healthcare Limited.

What Is Fueling Growth in the Onychomycosis Market?

The expansion of the onychomycosis market is projected to be fueled by the escalating diabetes patient base. Diabetes, a long-term illness, results from either inadequate insulin production by the pancreas or the body’s inefficient use of insulin. Onychomycosis, a recurring foot issue in diabetics, can be controlled via early detection and management of related complications. Consequently, the prevalence of diabetes spurs the demand within the onychomycosis market. For example, in June 2024, the National Health Service, a UK government department, revealed that in 2023, over half a million (549,000) more individuals in England were considered at risk for type 2 diabetes. This pushed the total of those tagged with non-diabetic hyperglycemia or pre-diabetes registered with a GP to 3,615,330. When compared with the 2022 figure of 3,065,825, this is a marked increase of nearly 20%. Therefore, the growth of the onychomycosis market is being fueled by the increasing prevalence of diabetes.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12197&type=smp

Which Onychomycosis Market Segments Are Growing the Fastest?

The onychomycosis market covered in this report is segmented –

1) By Type: Distal Subungual Onychomycosis (DSO), White Superficial Onychomycosis (WSO), Proximal Subungual Onychomycosis (PSO), Candida Onychomycosis, Other Types

2) By Treatment: Drug Treatment, Topical Therapy, Other Treatments

3) By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:

1) By Distal Subungual Onychomycosis (DSO): Dermatophyte Infections, Mixed Infections

2) By White Superficial Onychomycosis (WSO): Trichophyton Mentagrophytes Infections, Other Non-Dermatophyte Infections

3) By Proximal Subungual Onychomycosis (PSO): Associated with Nail Psoriasis, Fungal Infections In Immunocompromised Patients

4) By Candida Onychomycosis: Candidal Nail Infections, Mixed Fungal-Candida Infections

5) By Other Types: Total Nail Dystrophy, Secondary Onychomycosis

Which Industry Trends Are Shaping the Future of the Onychomycosis Market?

One prominent trend gaining traction within the onychomycosis market is product innovation. Market-leading companies are creating cutting-edge products in an effort to retain their market share. For example, Vanda Pharmaceuticals Inc., a U.S.-based biopharmaceutical firm, reported in January 2024 they had achieved Food and Drug Administration (FDA) sanction for VTR-297 as a treatment for onychomycosis. The drug, noted for its antifungal abilities, specifically against dermatophytes and various fungi, acts as a histone deacetylase (HDAC) inhibitor. This functioning method is pivotal when aiming to target the pathogens that cause onychomycosis. As VTR-297 is a topical medicine, it is applied directly to the affected nail areas, serving to reduce systemic exposure and the potential side effects generally linked with orally taken antifungals.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/onychomycosis-global-market-report

Which Countries Are Leading the Onychomycosis Market?

North America was the largest region in the onychomycosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onychomycosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12197

This Report Delivers Insight On:

1. How big is the onychomycosis market, and how is it changing globally?

2. Who are the major companies in the onychomycosis market, and how are they performing?

3. What are the key opportunities and risks in the onychomycosis market right now?

4. Which products or customer segments are growing the most in the onychomycosis market?

5. What factors are helping or slowing down the growth of the onychomycosis market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model